CA1062613A - Enteric capsules - Google Patents
Enteric capsulesInfo
- Publication number
- CA1062613A CA1062613A CA250,411A CA250411A CA1062613A CA 1062613 A CA1062613 A CA 1062613A CA 250411 A CA250411 A CA 250411A CA 1062613 A CA1062613 A CA 1062613A
- Authority
- CA
- Canada
- Prior art keywords
- capsules
- ammonium salt
- gelatin
- enteric
- methacrylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 64
- 108010010803 Gelatin Proteins 0.000 claims abstract description 18
- 229920000159 gelatin Polymers 0.000 claims abstract description 18
- 239000008273 gelatin Substances 0.000 claims abstract description 18
- 235000019322 gelatine Nutrition 0.000 claims abstract description 18
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 18
- 150000003863 ammonium salts Chemical class 0.000 claims abstract description 15
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 14
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims abstract description 6
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims abstract description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims abstract description 5
- 239000003086 colorant Substances 0.000 claims abstract description 4
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 238000000465 moulding Methods 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 210000004051 gastric juice Anatomy 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 230000015556 catabolic process Effects 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 125000005397 methacrylic acid ester group Chemical group 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 abstract description 6
- 239000004014 plasticizer Substances 0.000 abstract description 4
- 230000009858 acid secretion Effects 0.000 abstract description 3
- 210000002011 intestinal secretion Anatomy 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 30
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- -1 hydroxy-propyl Chemical group 0.000 description 10
- 229920001577 copolymer Polymers 0.000 description 9
- 238000007598 dipping method Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 230000032683 aging Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 239000000908 ammonium hydroxide Substances 0.000 description 5
- 238000007922 dissolution test Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000007887 hard shell capsule Substances 0.000 description 3
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- VQLYBLABXAHUDN-UHFFFAOYSA-N bis(4-fluorophenyl)-methyl-(1,2,4-triazol-1-ylmethyl)silane;methyl n-(1h-benzimidazol-2-yl)carbamate Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1.C=1C=C(F)C=CC=1[Si](C=1C=CC(F)=CC=1)(C)CN1C=NC=N1 VQLYBLABXAHUDN-UHFFFAOYSA-N 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010961 commercial manufacture process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960000901 mepacrine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56897475A | 1975-04-17 | 1975-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1062613A true CA1062613A (en) | 1979-09-18 |
Family
ID=24273552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA250,411A Expired CA1062613A (en) | 1975-04-17 | 1976-04-15 | Enteric capsules |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JPS51128421A (forum.php) |
| AU (1) | AU497485B2 (forum.php) |
| BE (1) | BE840814A (forum.php) |
| CA (1) | CA1062613A (forum.php) |
| CH (1) | CH598825A5 (forum.php) |
| DE (1) | DE2616748C2 (forum.php) |
| FR (1) | FR2307523A1 (forum.php) |
| GB (2) | GB1529902A (forum.php) |
| IT (1) | IT1058141B (forum.php) |
| MX (1) | MX3955E (forum.php) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4655840A (en) * | 1982-03-26 | 1987-04-07 | Warner-Lambert Company | Hydrophilic polymer compositions for injection molding |
| EG16027A (en) * | 1982-03-26 | 1986-12-30 | Warner Lambert Co | Hydrophilic polymer composition for injection molding |
| FR2617047B1 (fr) * | 1987-06-23 | 1991-05-10 | Sanofi Sa | Composition de gelatine resistant au tannage, capsules a base de cette composition et leur application pharmaceutique, notamment au fenofibrate |
| GB8721455D0 (en) * | 1987-09-11 | 1987-10-21 | Lilly Industries Ltd | Capsules |
| GB2218994B (en) * | 1988-05-26 | 1992-01-15 | Warner Lambert Co | New polymer composition |
| JP5253235B2 (ja) * | 2009-03-02 | 2013-07-31 | クオリカプス株式会社 | 腸溶性カプセル |
| KR101705204B1 (ko) * | 2009-09-11 | 2017-02-09 | 롯데정밀화학 주식회사 | 장용성 경질 캡슐용 수성 조성물, 장용성 경질 캡슐의 제조방법 및 장용성 경질 캡슐 |
| KR101182827B1 (ko) * | 2010-06-11 | 2012-09-14 | 삼성정밀화학 주식회사 | 장용성 경질 캡슐의 제조방법 및 장용성 경질 캡슐 |
| KR101787481B1 (ko) * | 2010-10-21 | 2017-10-18 | 롯데정밀화학 주식회사 | 장용성 경질 캡슐용 조성물 및 상기 조성물을 사용하여 제조된 장용성 경질 캡슐 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1064688B (de) * | 1952-05-01 | 1959-09-03 | Eastman Kodak Co | Verfahren zur Herstellung von Duenndarmkapseln |
-
1976
- 1976-04-14 MX MX17176U patent/MX3955E/es unknown
- 1976-04-15 AU AU13061/76A patent/AU497485B2/en not_active Expired
- 1976-04-15 IT IT4906076A patent/IT1058141B/it active
- 1976-04-15 DE DE19762616748 patent/DE2616748C2/de not_active Expired
- 1976-04-15 CA CA250,411A patent/CA1062613A/en not_active Expired
- 1976-04-15 GB GB908878A patent/GB1529902A/en not_active Expired
- 1976-04-15 BE BE166219A patent/BE840814A/xx not_active IP Right Cessation
- 1976-04-15 CH CH486976A patent/CH598825A5/xx not_active IP Right Cessation
- 1976-04-15 GB GB1572076A patent/GB1529901A/en not_active Expired
- 1976-04-15 FR FR7611203A patent/FR2307523A1/fr active Granted
- 1976-04-15 JP JP4190776A patent/JPS51128421A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BE840814A (fr) | 1976-08-02 |
| IT1058141B (it) | 1982-04-10 |
| GB1529901A (en) | 1978-10-25 |
| FR2307523A1 (fr) | 1976-11-12 |
| FR2307523B1 (forum.php) | 1978-08-25 |
| MX3955E (es) | 1981-10-15 |
| DE2616748A1 (de) | 1976-10-28 |
| CH598825A5 (forum.php) | 1978-05-12 |
| AU1306176A (en) | 1977-10-20 |
| DE2616748C2 (de) | 1987-01-08 |
| JPS51128421A (en) | 1976-11-09 |
| GB1529902A (en) | 1978-10-25 |
| AU497485B2 (en) | 1978-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4138013A (en) | Enteric capsules | |
| US10898440B2 (en) | Bulk enteric capsule shells | |
| US10874619B2 (en) | Acid resistant capsules | |
| KR0155563B1 (ko) | 대장 붕괴성 경질 캡슐 | |
| JP4838202B2 (ja) | カプセル用のポリマーフィルム組成物 | |
| RU1820837C (ru) | Способ получени капсул | |
| JP5248739B2 (ja) | 腸溶性調製物 | |
| KR100580826B1 (ko) | 경질 캅셀의 제조방법 | |
| BRPI0618175A2 (pt) | tecnologia para revestimento de múltiplas camadas para o mascaramento de sabor | |
| JPS62246513A (ja) | 二重壁で被覆した医薬のマイクロカプセルからなる徐放性薬剤 | |
| EP0056825B1 (en) | A process for producing a pharmaceutical capsule having enteric properties | |
| US3826666A (en) | Enteric capsules | |
| CA1062613A (en) | Enteric capsules | |
| US2491475A (en) | Enteric capsule | |
| JP2000202003A (ja) | 硬質カプセル及びその製造方法 | |
| WO2002039982A1 (en) | Oral formulations for localized colonic release and the method of preparation thereof | |
| JPH0624962A (ja) | 腸溶徐放性製剤 | |
| US11904056B2 (en) | Capsule shell comprising a core-shell polymer and a cellulose | |
| JP2022123274A (ja) | 腸溶性硬質カプセル | |
| GB2043442A (en) | Film-coated pharmaceutical gelatine capsules | |
| US20250177313A1 (en) | Formulation of intrinsically acid-resistant vegetarian-based and gelatin-based soft gel capsules for pharmaceutical/ nutraceutical products | |
| CA3119012C (en) | Formulation of intrinsically acid-resistant vegetarian-based and gelatin-based soft gel capsules for pharmaceutical/nutraceutical products | |
| JPH07121859B2 (ja) | 徐放性カプセル剤 |